Showing 901 - 920 results of 104,426 for search '(( 2 de decrease ) OR ( 5 ((((ng decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 1.37s Refine Results
  1. 901
  2. 902
  3. 903
  4. 904
  5. 905
  6. 906
  7. 907

    CICR in NG2 cells. by Christian Haberlandt (226735)

    Published 2011
    “…Traces represent the average of 5 cells. (B) Single pulses (gray box, lower trace) induced [Ca<sup>2+</sup>]<sub>i</sub> elevations that were sensitive to thapsigargin (1 µM, elevation decreased to 10%) indicating a contribution of Ca<sup>2+</sup>-release from intracellular stores. …”
  8. 908
  9. 909
  10. 910
  11. 911
  12. 912
  13. 913
  14. 914

    Table_1_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  15. 915

    Table_3_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  16. 916

    Table_4_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  17. 917

    Image_1_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.PDF by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  18. 918
  19. 919
  20. 920